Azitra (AZTR) Cash from Financing Activities (2022 - 2026)
Azitra (AZTR) posted Cash from Financing Activities of $10.5 million for Q1 2026, up 188.18% on a QoQ basis from $3.6 million in Q4 2025, and up 501.42% year-over-year from $1.7 million in Q1 2025.
Azitra (AZTR) Cash from Financing Activities (2022 - 2026) Analysis & Trends
Azitra's Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $10.5 million for Q1 2026.
- Quarterly Cash from Financing Activities rose 501.42% year-over-year to $10.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.7 million (up 64.23% YoY) and the FY2025 annual result came in at $8.9 million, down 33.04% from the prior year.
- Cash from Financing Activities was $10.5 million for Q1 2026 at Azitra, up from $3.6 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $10.5 million in Q1 2026 and bottomed at -$272080.0 in Q1 2023.
- A 5-year average of $2.9 million and a median of $1.7 million in 2025 frame the typical range for Cash from Financing Activities.
- Peak annual rise in Cash from Financing Activities reached 402621.1% in 2024, while the deepest fall reached 100.34% in 2024.
- Azitra's Cash from Financing Activities stood at -$176183.0 in 2022, then jumped by 97.08% to -$5146.0 in 2023, then gained by 26.51% to -$3782.0 in 2024, then jumped by 96416.08% to $3.6 million in 2025, then jumped by 188.18% to $10.5 million in 2026.
- Business Quant data shows AZTR's Cash from Financing Activities at $10.5 million in Q1 2026, $3.6 million in Q4 2025, and $2.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,792.52 Bn | 1,792.46 Bn | - | - |
| 2 | Akari Therapeutics | 999.95 Bn | 999.95 Bn | - | 53,000.00 |
| 3 | BeOne Medicines | 475.97 Bn | 471.17 Bn | 1.35 Bn | 68.63 Mn |
| 4 | Vertex Pharmaceuticals | 124.91 Bn | 117.66 Bn | 2.59 Bn | -538.80 Mn |
| 5 | Regeneron Pharmaceuticals | 72.31 Bn | 63.56 Bn | 3.31 Bn | -802.20 Mn |
| 6 | Belite Bio | 62.01 Bn | 62.01 Bn | - | - |
| 7 | Argenx Se | 54.23 Bn | 49.04 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 38.31 Bn | 35.30 Bn | 959.66 Mn | 15.71 Mn |
| 9 | Revolution Medicines | 36.16 Bn | 36.16 Bn | - | 238.74 Mn |
| 10 | Azitra | 2.05 Mn | 2.05 Mn | - | 10.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.50 Mn |
| Mar 31, 2026 | 10.50 Mn |
| Dec 31, 2025 | 3.64 Mn |
| Dec 31, 2025 | 3.64 Mn |
| Sep 30, 2025 | 2.84 Mn |
| Sep 30, 2025 | 2.84 Mn |
| Jun 30, 2025 | 690,343.00 |
| Jun 30, 2025 | 690,343.00 |
| Mar 31, 2025 | 1.75 Mn |
| Mar 31, 2025 | 1.75 Mn |
| Dec 31, 2024 | -3,782.00 |
| Dec 31, 2024 | -3,782.00 |
| Sep 30, 2024 | 9.04 Mn |
| Sep 30, 2024 | 9.04 Mn |
| Jun 30, 2024 | -21,381.00 |
| Jun 30, 2024 | -21,381.00 |
| Mar 31, 2024 | 4.31 Mn |
| Mar 31, 2024 | 4.31 Mn |
| Dec 31, 2023 | -5,146.00 |
| Dec 31, 2023 | -5,146.00 |